{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:25:08Z","timestamp":1767651908532,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"Background<\/jats:title>Bromodomain and extracellular terminal (BET) family (including BRD2, BRD3, and BRD4) is considered to be a major driver of cancer cell growth and a new target for cancer therapy. Currently, more than 30 targeted inhibitors have shown significant inhibitory effects against various tumors in preclinical and clinical trials. However, the expression levels, gene regulatory networks, prognostic value, and target prediction of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> in adrenocortical carcinoma (ACC) have not been fully elucidated. Therefore, this study aimed to systematically analyze the expression, gene regulatory network, prognostic value, and target prediction of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> in patients with ACC, and elucidated the association between BET family expression and ACC. We also provided useful information on BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> and potential new targets for the clinical treatment of ACC.<\/jats:p><\/jats:sec>Methods<\/jats:title>We systematically analyzed the expression, prognosis, gene regulatory network, and regulatory targets of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> in ACC using multiple online databases, including cBioPortal, TRRUST, GeneMANIA, GEPIA, Metascape, UALCAN, LinkedOmics, and TIMER.<\/jats:p><\/jats:sec>Results<\/jats:title>The expression levels of BRD3<\/jats:italic> and BRD4<\/jats:italic> were significantly upregulated in ACC patients at different cancer stages. Moreover, the expression of BRD4<\/jats:italic> was significantly correlated with the pathological stage of ACC. ACC patients with low BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> expressions had longer survival than patients with high BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> expressions. The expression of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> was altered by 5%, 5%, and 12% in 75 ACC patients, respectively. The frequency of gene alterations in the 50 most frequently altered BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> neighboring genes in these ACC patients were \u226525.00%, \u226525.00%, and \u226544.44%, respectively. BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> and their neighboring genes form a complex network of interactions mainly through co-expression, physical interactions, and shared protein domains. Molecular functions related to BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> and their neighboring genes mainly include protein-macromolecule adaptor activity, cell adhesion molecule binding, and aromatase activity. Chemokine signaling pathway, thiamine metabolism, and olfactory transduction were found to be enriched as per the KEGG pathway analysis. SP1, NPM1, STAT3, and TP53 are key transcription factors for BRD2<\/jats:italic>, BRD4<\/jats:italic>, and their neighboring genes. MiR-142-3P, miR-484, and miR-519C were the main miRNA targets of BRD2<\/jats:italic>, BRD3<\/jats:italic>, BRD4, and their neighboring genes. We analyzed the mRNA sequencing data from 79 patients with ACC and found that ZSCAN12<\/jats:italic>, DHX16<\/jats:italic>, PRPF4B<\/jats:italic>, EHMT1<\/jats:italic>, CDK5RAP2<\/jats:italic>, POMT1<\/jats:italic>, WIZ<\/jats:italic>, ZNF543<\/jats:italic>, and AKAP8<\/jats:italic> were the top nine genes whose expression were positively associated with BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> expression. The expression level of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> positively correlated with B cell and dendritic cell infiltration levels. BRD4<\/jats:italic>-targeted drug PFI-1 and (BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic>)-targeted drug I-BET-151 may have good inhibitory effects on the SW13 cell line.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The findings of this study provide a partial basis for the role of BRD2<\/jats:italic>, BRD3<\/jats:italic>, and BRD4<\/jats:italic> in the occurrence and development of ACC. In addition, this study also provides new potential therapeutic targets for ACC, which can serve as a reference for future basic and clinical research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1089531","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:01:02Z","timestamp":1675054862000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets"],"prefix":"10.3389","volume":"14","author":[{"given":"Yongli","family":"Situ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jv","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongshi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1853e1878","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: prevalence and incidence of endocrine and metabolic disorders in the united states: a comprehensive review","volume":"94","author":"Golden","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"282e326","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab866","article-title":"Pathological and genetic stratification for management of adrenocortical carcinoma","volume":"107","author":"Clay","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"395e407","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"273e289","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"186e195","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4551e4564","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/s12885-017-3506-z","article-title":"Outcome after resection of adrenocortical carcinoma liver metastases: a retrospective study","volume":"17","author":"Baur","year":"2017","journal-title":"BMC Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"480e490","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J Am Coll Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"585e591","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1456e1461","DOI":"10.1245\/s10434-012-2760-1","article-title":"Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience","volume":"20","author":"Mir","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B13","article-title":"BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J Med Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.847701","article-title":"Post-translational modifications of BRD4: Therapeutic targets for tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2081464","article-title":"Pathological stage-associated non-coding RNA long intergenic non-protein coding RNA 1234 (LINC01234) participation in cell cycle regulation in adrenocortical carcinoma through bromodomain-containing protein 4 (BRD4) expression mediation via sponging microRNA (miR)-140-3p","volume":"13","author":"Zhu","year":"2022","journal-title":"Bioengineered."},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-021-01424-5","article-title":"The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis","volume":"20","author":"Drumond-Bock","year":"2021","journal-title":"Mol Cancer."},{"key":"B21","article-title":"Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells","volume":"55","author":"Zia","year":"1995","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/BST20190033","article-title":"Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target","volume":"48","author":"Griffiths","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/17246008211063501","article-title":"System analysis of VEGFA in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets","volume":"37","author":"Situ","year":"2022","journal-title":"Int J Biol Markers."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/cells9112356","article-title":"The tubulin code in mitosis and cancer","volume":"9","author":"Lopes","year":"2020","journal-title":"Cells."},{"key":"B26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.bbamcr.2013.12.016","article-title":"Regulation of histone modifying enzymes by the ubiquitin-proteasome system","volume":"1843","author":"Zou","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7150\/ijms.7178","article-title":"Prolyl endopeptidase activity is correlated with colorectal cancer prognosis","volume":"11","author":"Larrinaga","year":"2014","journal-title":"Int J Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02120","article-title":"Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis","volume":"10","author":"L\u00e4ubli","year":"2019","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.017","article-title":"Ca2+ fluxes and cancer","volume":"78","author":"Marchi","year":"2020","journal-title":"Mol Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0542-0","article-title":"Expression of aromatase and estrogen receptors in human adrenocortical tumors","volume":"452","author":"Barzon","year":"2008","journal-title":"Virchows Arch"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0200","article-title":"Multiple aberrant hormone receptors in cushing's syndrome","volume":"173","author":"El Ghorayeb","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance","volume":"40","author":"Yousefi","year":"2021","journal-title":"Oncogene."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.04.053","article-title":"CXCL13\/CXCR5 signaling axis in cancer","volume":"227","author":"Hussain","year":"2019","journal-title":"Life Sci"},{"key":"B35","article-title":"The role of thiamine in cancer: possible genetic and cellular signaling mechanisms","volume":"10","author":"Lu'o'ng","year":"2013","journal-title":"Cancer Genomics Proteomics."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2014.09.002","article-title":"Quantitative phosphoproteomics reveals the protein tyrosine kinase Pyk2 as a central effector of olfactory receptor signaling in prostate cancer cells","volume":"1854","author":"Wiese","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13148","article-title":"Sp1 and the 'hallmarks of cancer'","volume":"282","author":"Beishline","year":"2015","journal-title":"FEBS J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1130-1","article-title":"Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis","volume":"16","author":"Zhu","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9482-7","article-title":"A novel TP53 mutation associated with TWIST1 and SIP1 expression in an aggressive adrenocortical carcinoma","volume":"28","author":"Bulzico","year":"2017","journal-title":"Endocr Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S304526","article-title":"Nucleolin-targeting AS1411 aptamer-modified micelle for the Co-delivery of doxorubicin and miR-519c to improve the therapeutic efficacy in hepatocellular carcinoma treatment","volume":"16","author":"Liang","year":"2021","journal-title":"Int J Nanomedicine."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/138624","article-title":"lncRNA PSMA3-AS1 promotes the progression of non-small cell lung cancer through targeting miR-17-5p\/PD-L1","volume":"30","author":"Cheng","year":"2021","journal-title":"Adv Clin Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-021-09919-8","article-title":"MiR-519d-3p enhances the sensitivity of non-small-cell lung cancer to tyrosine kinase inhibitors","volume":"32","author":"Zhen","year":"2021","journal-title":"Mamm Genome."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2021.102.15","article-title":"Immune microenvironment comparation study between EGFR mutant and EGFR wild type lung adenocarcinoma patients based on TCGA database","volume":"24","author":"Zhu","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1089531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:01:07Z","timestamp":1675054867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1089531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":43,"alternative-id":["10.3389\/fendo.2023.1089531"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1089531","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"article-number":"1089531"}}